05 March 2007
Munich, Germany, -- Affectis Pharmaceuticals AG announced today that it has extended its research collaboration with Mitsubishi Pharma. The collaboration, established in February 2005, called for Affectis to use its expertise to assist Mitsubishi in developing novel therapeutics for the treatment of affective disorders and has now been expanded by another project.
"I would like to recognize the employees of Mitsubishi and Affectis, who jointly have built the trust and respect that resulted in the renewal of this collaboration," said Herbert Stadler, CEO of Affectis. "Following the recent announcement of our inlicensing agreement with Palau Pharma and the rapid progress of our in-house P2X7 program, I am delighted with the momentum we have created in the past 12 months."
"We are pleased with the accomplishments made to date," stated Dr Nakajima, Executive Officer/Division Manager of the Pharmaceutical Research Division for Mitsubishi Pharma. "The progress we have achieved together during the last two years was extremely valuable. We look forward to continuing to work with Affectis to bring forward the development of new drugs for the treatment of affective disorders.”
Contact for Affectis Pharmaceuticals AG:
Sabina van den Brandt
Kraepelinstrasse 2
D-80804 Munich, Germany
Tel: +49 (0)89 - 306 22 - 591
Fax: +49 (0)89 - 306 22 - 370
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.affectis.com
| File | File size |
|---|---|
 03-2007 Affectis - Mitsubishi Pharma engl.pdf | 23 Kb |
Copyright © 2012 Affectis Pharmaceuticals AG. All Rights Reserved.
